Immuneering's MEK inhibitor IMM-1-104 shows positive Phase 2a results in pancreatic cancer with 43% response rate when ...

Eli Lilly joins FDA lawsuit over tirzepatide shortage listing, as Outsourcing Facilities Association challenges removal of ...

Vertex partners with Orna Therapeutics to develop in vivo gene editing treatments for sickle cell disease and beta ...

Candid Therapeutics commits $925M for WuXi Biologics' T cell engager rights. CEO Ken Song aims for human trials in 2026, ...

Johnson & Johnson said its recently approved Rybrevant and Lazcluze combination therapy topped Tagrisso on overall survival ...

XyloCor raises $67.5M Series B led by Jeito Capital for XC001 gene therapy trials in cardiac patients. CEO Al Gianchetti says ...

Avenzo Therapeutics pays $50M upfront to DualityBio for rights to bispecific antibody-drug conjugate DB-1418. Deal follows ...

Pfizer has re-upped its drug discovery deal with AI startup PostEra to develop small molecule drugs and new warheads for antibody-drug conjugates, a major area of focus for the drugmaker ...

Highlander Health, the clinical trial startup co-founded by former Verily execs Amy Abernethy and Brad Hirsch, is acquiring ...

A 20-year-old biotech working on small molecule treatments for cardiovascular and skeletal muscle diseases has rebranded and ...

Acelyrin has offered a more detailed look at positive Phase 2 data for its thyroid eye disease drug candidate as it tees up ...

San Diego-based Velia Therapeutics, which was working on so-called microproteins, is in the process of winding down about two ...